gsk201509016k2.htm

SECURITIES AND EXCHANGE COMMISSION 

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of 

the Securities Exchange Act of 1934

For period ending September 2015

(Name of registrant) 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices) 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F 

Form 20-F x Form 40-F 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934. 

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 28 August 2015, of changes in the interests of the following Person Discharging Managerial Responsibilities ('PDMR'), following increases in their actual interests and the notional matching element in Ordinary Shares, at a price of £12.98 per Ordinary Share, following the re-investment of dividends paid on Ordinary Shares held in the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards.

PDMR	Number of Ordinary Shares acquired under the personal contribution element of the plan	Number of Ordinary Shares acquired under the matching element of the plan (GSK contribution)
Ms C Thomas	174	174

V A Whyte

Company Secretary

1 September 2015

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. 

Date: September 01, 2015

----------------------

Authorised Signatory for and on

behalf of GlaxoSmithKline plc